Annual FCF
-$228.37 M
+$9.85 M+4.13%
31 December 2023
Summary:
REGENXBIO annual free cash flow is currently -$228.37 million, with the most recent change of +$9.85 million (+4.13%) on 31 December 2023. During the last 3 years, it has fallen by -$147.44 million (-182.18%). RGNX annual FCF is now -269.54% below its all-time high of $134.70 million, reached on 31 December 2021.RGNX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$40.88 M
+$5.10 M+11.09%
30 September 2024
Summary:
REGENXBIO quarterly free cash flow is currently -$40.88 million, with the most recent change of +$5.10 million (+11.09%) on 30 September 2024. Over the past year, it has increased by +$9.97 million (+19.61%). RGNX quarterly FCF is now -112.50% below its all-time high of $326.88 million, reached on 31 December 2021.RGNX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$184.74 M
+$9.97 M+5.12%
30 September 2024
Summary:
REGENXBIO TTM free cash flow is currently -$184.74 million, with the most recent change of +$9.97 million (+5.12%) on 30 September 2024. Over the past year, it has increased by +$46.58 million (+20.14%). RGNX TTM FCF is now -229.29% below its all-time high of $142.89 million, reached on 31 March 2022.RGNX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RGNX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.1% | +19.6% | +20.1% |
| 3 y3 years | -182.2% | +33.2% | -11.6% |
| 5 y5 years | -349.9% | -28.4% | -81.3% |
RGNX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -269.5% | +4.1% | -112.5% | +52.3% | -229.3% | +28.1% |
| 5 y | 5 years | -269.5% | +4.1% | -112.5% | +52.3% | -229.3% | +28.1% |
| alltime | all time | -269.5% | +4.1% | -112.5% | +52.3% | -229.3% | +28.1% |
REGENXBIO Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$40.88 M(-11.1%) | -$184.74 M(-5.1%) |
| June 2024 | - | -$45.97 M(-17.9%) | -$194.72 M(-2.0%) |
| Mar 2024 | - | -$56.01 M(+33.7%) | -$198.64 M(-13.0%) |
| Dec 2023 | -$228.37 M(-4.1%) | -$41.89 M(-17.6%) | -$228.37 M(-1.3%) |
| Sept 2023 | - | -$50.85 M(+1.9%) | -$231.32 M(-2.0%) |
| June 2023 | - | -$49.90 M(-41.8%) | -$235.98 M(-8.2%) |
| Mar 2023 | - | -$85.74 M(+91.2%) | -$257.07 M(+7.9%) |
| Dec 2022 | -$238.21 M(-276.8%) | -$44.84 M(-19.2%) | -$238.21 M(-278.4%) |
| Sept 2022 | - | -$55.51 M(-21.8%) | $133.51 M(+4.5%) |
| June 2022 | - | -$70.99 M(+6.1%) | $127.82 M(-10.5%) |
| Mar 2022 | - | -$66.88 M(-120.5%) | $142.89 M(+6.1%) |
| Dec 2021 | $134.70 M(-266.4%) | $326.88 M(-634.1%) | $134.70 M(-181.3%) |
| Sept 2021 | - | -$61.20 M(+9.5%) | -$165.60 M(+12.7%) |
| June 2021 | - | -$55.91 M(-25.5%) | -$146.94 M(+26.9%) |
| Mar 2021 | - | -$75.07 M(-382.4%) | -$115.80 M(+43.1%) |
| Dec 2020 | -$80.93 M(-32.2%) | $26.58 M(-162.5%) | -$80.93 M(-39.6%) |
| Sept 2020 | - | -$42.53 M(+71.7%) | -$134.05 M(+8.7%) |
| June 2020 | - | -$24.77 M(-38.4%) | -$123.35 M(-3.5%) |
| Mar 2020 | - | -$40.20 M(+51.5%) | -$127.88 M(+7.1%) |
| Dec 2019 | -$119.42 M | -$26.54 M(-16.6%) | -$119.42 M(+17.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$31.83 M(+8.6%) | -$101.92 M(+9.6%) |
| June 2019 | - | -$29.30 M(-7.7%) | -$93.01 M(-2529.8%) |
| Mar 2019 | - | -$31.75 M(+251.7%) | $3.83 M(-95.8%) |
| Dec 2018 | $91.37 M(-240.2%) | -$9.03 M(-60.6%) | $91.37 M(+8.2%) |
| Sept 2018 | - | -$22.93 M(-133.9%) | $84.47 M(-5.9%) |
| June 2018 | - | $67.54 M(+21.1%) | $89.81 M(+713.0%) |
| Mar 2018 | - | $55.79 M(-450.3%) | $11.05 M(-117.0%) |
| Dec 2017 | -$65.15 M(+14.9%) | -$15.93 M(-9.4%) | -$65.15 M(-12.1%) |
| Sept 2017 | - | -$17.59 M(+56.6%) | -$74.08 M(+5.0%) |
| June 2017 | - | -$11.23 M(-45.0%) | -$70.54 M(+2.5%) |
| Mar 2017 | - | -$20.41 M(-17.9%) | -$68.81 M(+21.4%) |
| Dec 2016 | -$56.71 M(+146.2%) | -$24.86 M(+77.0%) | -$56.71 M(+55.7%) |
| Sept 2016 | - | -$14.04 M(+47.7%) | -$36.42 M(+18.0%) |
| June 2016 | - | -$9.51 M(+14.5%) | -$30.85 M(+4.4%) |
| Mar 2016 | - | -$8.30 M(+81.6%) | -$29.56 M(+28.3%) |
| Dec 2015 | -$23.04 M(+860.3%) | -$4.57 M(-46.1%) | -$23.04 M(+24.8%) |
| Sept 2015 | - | -$8.47 M(+3.2%) | -$18.47 M(+84.8%) |
| June 2015 | - | -$8.21 M(+361.0%) | -$9.99 M(+461.0%) |
| Mar 2015 | - | -$1.78 M | -$1.78 M |
| Dec 2014 | -$2.40 M(-20.4%) | - | - |
| Dec 2013 | -$3.01 M | - | - |
FAQ
- What is REGENXBIO annual free cash flow?
- What is the all time high annual FCF for REGENXBIO?
- What is REGENXBIO annual FCF year-on-year change?
- What is REGENXBIO quarterly free cash flow?
- What is the all time high quarterly FCF for REGENXBIO?
- What is REGENXBIO quarterly FCF year-on-year change?
- What is REGENXBIO TTM free cash flow?
- What is the all time high TTM FCF for REGENXBIO?
- What is REGENXBIO TTM FCF year-on-year change?
What is REGENXBIO annual free cash flow?
The current annual FCF of RGNX is -$228.37 M
What is the all time high annual FCF for REGENXBIO?
REGENXBIO all-time high annual free cash flow is $134.70 M
What is REGENXBIO annual FCF year-on-year change?
Over the past year, RGNX annual free cash flow has changed by +$9.85 M (+4.13%)
What is REGENXBIO quarterly free cash flow?
The current quarterly FCF of RGNX is -$40.88 M
What is the all time high quarterly FCF for REGENXBIO?
REGENXBIO all-time high quarterly free cash flow is $326.88 M
What is REGENXBIO quarterly FCF year-on-year change?
Over the past year, RGNX quarterly free cash flow has changed by +$9.97 M (+19.61%)
What is REGENXBIO TTM free cash flow?
The current TTM FCF of RGNX is -$184.74 M
What is the all time high TTM FCF for REGENXBIO?
REGENXBIO all-time high TTM free cash flow is $142.89 M
What is REGENXBIO TTM FCF year-on-year change?
Over the past year, RGNX TTM free cash flow has changed by +$46.58 M (+20.14%)